Key Points
-
The transaction involved 7,062 shares with an estimated value of $529,650 as of the transaction date.
-
The traded shares represented ~10% of the equity stake held before the filing.
-
The activity was limited to direct equity holdings; no indirect entities were disclosed as part of the transaction.
-
The sale was executed under a Rule 10b5-1 trading plan established on June 5, 2026, indicating a pre-scheduled liquidity event.
Ryan M. Bartolucci, Chief Accounting Officer, reported a sale of 7,062 shares of Tempus AI(NASDAQ:TEM) Class A Common Stock on September 17, 2026, according to a recent SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Transaction value | $529,650 |
| Shares sold | 7,062 |
| Post-transaction shares (directly held) | 60,804 |
| Post-transaction value | $4.89 million |
Transaction value based on SEC Form 4 weighted average sale price ($75.00); post-transaction value based on September 17, 2026 market close ($80.36).
Key questions
- What was the regulatory basis for this transaction?
The sale was conducted under a Rule 10b5-1 trading plan that Ryan M. Bartolucci adopted on June 5, 2026. This arrangement allows company insiders to schedule stock trades in advance to manage personal equity holdings without concerns regarding material non-public information. - How does this impact the insider’s total direct equity position?
Following the disposition of 7,062 shares, the Chief Accounting Officer maintains a direct ownership position of 60,804 shares of Class A Common Stock. The firm reported no indirect holdings in this filing. - What is the recent performance context for the stock?
At the time of the transaction on September 17, 2026, the company had generated a one-year total return of -7%. The stock was priced at $77.84 as of the September 18, 2026 market close. - What is the scope of the company’s current operations?
Tempus AI operates a healthcare technology platform in the United States, providing bi-directional integrations between clinical desktops and laboratory diagnostic capabilities. The firm utilizes an analytics platform and a repository of multimodal data to support healthcare providers through its NGS tests and clinical applications.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-09-18) | $77.84 |
| Market Capitalization | $14.0 billion |
| Revenue (TTM) | $1.4 billion |
| Net Income (TTM) | -$254.4 million |
Company Snapshot
- Tempus AI operates a closed-loop healthcare technology platform that integrates clinician workflows with laboratory diagnostic capabilities, analytics, and multimodal data repositories, generating revenue primarily through its Tempus platform and Hub clinical application for next-generation sequencing tests.
- The company monetizes its healthcare information services through a technology-enabled diagnostics model that provides end-to-end solutions for healthcare providers, combining proprietary analytics with bi-directional clinical integrations to drive adoption and utilization.
- Tempus AI serves physicians, healthcare providers, and clinical laboratories seeking advanced diagnostic capabilities and data-driven insights, with a primary focus on oncology and precision medicine applications within the United States healthcare market.
Tempus AI is a healthcare technology company with a $14 billion market capitalization and 3,800 employees headquartered in Chicago. The company has achieved $1.4 billion in TTM revenue while investing substantially in platform development and market expansion, as evidenced by a net loss of $254 million TTM.
Its competitive advantage derives from its integrated full-stack platform that combines clinical workflow optimization with advanced diagnostics and proprietary data analytics, positioning it as a differentiated player in the healthcare information services sector.
What this transaction means for investors
This sale shouldn’t concern investors. It represented a small percentage of the executive’s holdings in the company’s stock. Moreover, it was executed under a Rule 10b5-1 plan to avoid concerns of acting on non-public information.
The sale followed a 30% rebound in the stock year to date, driven by continued growth in the business. TTM revenue grew 50% year over year to $1.4 billion.
Tempus AI is still not profitable, but investors are hopeful that continued growth in the business will lead to earnings down the road. Analysts currently expect the company’s adjusted earnings to hit $0.71 by 2028, reflecting a high annualized growth rate once the company hits breakeven.
Should you buy stock in Tempus AI right now?
Before you buy stock in Tempus AI, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Tempus AI wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $389,154!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,406,303!*
Now, it’s worth noting Stock Advisor’s total average return is 949% — a market-crushing outperformance compared to 214% for the S&P 500. Don’t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of September 24, 2026.
John Ballard has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Tempus AI. The Motley Fool has a disclosure policy.